Health and Healthcare
Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)
Published:
We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity. Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:
STOCK (Ticker) Shares Short Change
Amgen (AMGN) 29,112,550 +10.89%
Biogen Idec (BIIB) 6,648,180 (9.58%)
Celgene (CELG) 25,751,400 +12.19%
Genzyme (GENZ) 6,536,150 +12.36%
Gilead (GILD) 25,557,168 (1.59%)
Imclone (IMCL) 4,252,342 (13.49%)
Medarex (MEDX) 30,181,760 (7.72%)
As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.
Jon C. Ogg
December 11, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
